PDS Biotechnology Total Assets Growth & History (PDSB)
PDS Biotechnology's total assets was $30.5M for fiscal 2025.
View full PDS Biotechnology company overviewPDS Biotechnology annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $30.5M | −$14.9M | −32.77% |
| 2024 | 2024-12-31 | $45.4M | −$14.0M | −23.63% |
| 2023 | 2023-12-31 | $59.4M | −$17.6M | −22.88% |
| 2022 | 2022-12-31 | $77.0M | $9.8M | +14.60% |
| 2021 | 2021-12-31 | $67.2M | $36.3M | +117.54% |
| 2020 | 2020-12-31 | $30.9M | $16.4M | +113.17% |
| 2019 | 2019-12-31 | $14.5M | −$21.7M | −59.99% |
| 2018 | 2018-12-31 | $36.2M | −$56.4M | −60.89% |
| 2017 | 2017-12-31 | $92.6M | −$18.3M | −16.49% |
| 2016 | 2016-12-31 | $110.9M | −$23.2M | −17.29% |
| 2015 | 2015-12-31 | $134.1M | $117.2M | +695.97% |
| 2014 | 2014-12-31 | $16.8M | — | — |
PDS Biotechnology quarterly total assets
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $8.8M | −$31.7M | −78.24% |
| Q1 2026 | 2026-03-31 | $24.7M | −$22.4M | −47.56% |
| Q4 2025 | 2025-12-31 | $30.5M | −$14.9M | −32.77% |
| Q3 2025 | 2025-09-30 | $34.7M | −$17.7M | −33.83% |
| Q2 2025 | 2025-06-30 | $40.5M | −$20.0M | −33.09% |
| Q1 2025 | 2025-03-31 | $47.0M | −$22.0M | −31.85% |
| Q4 2024 | 2024-12-31 | $45.4M | −$14.0M | −23.63% |
| Q3 2024 | 2024-09-30 | $52.5M | −$4.7M | −8.28% |
| Q2 2024 | 2024-06-30 | $60.5M | −$3.3M | −5.11% |
| Q1 2024 | 2024-03-31 | $69.0M | $557,740 | +0.81% |
| Q4 2023 | 2023-12-31 | $59.4M | −$17.6M | −22.88% |
| Q3 2023 | 2023-09-30 | $57.2M | −$17.7M | −23.63% |
| Q2 2023 | 2023-06-30 | $63.8M | $7.8M | +13.85% |
| Q1 2023 | 2023-03-31 | $68.4M | $7.4M | +12.14% |
| Q4 2022 | 2022-12-31 | $77.0M | $9.8M | +14.60% |
| Q3 2022 | 2022-09-30 | $74.9M | $3.1M | +4.37% |
| Q2 2022 | 2022-06-30 | $56.0M | −$21.4M | −27.64% |
| Q1 2022 | 2022-03-31 | $61.0M | $33.3M | +119.87% |
| Q4 2021 | 2021-12-31 | $67.2M | $36.3M | +117.54% |
| Q3 2021 | 2021-09-30 | $71.7M | $37.3M | +108.30% |
| Q2 2021 | 2021-06-30 | $77.4M | $57.3M | +285.16% |
| Q1 2021 | 2021-03-31 | $27.8M | $3.8M | +15.99% |
| Q4 2020 | 2020-12-31 | $30.9M | $16.4M | +113.17% |
| Q3 2020 | 2020-09-30 | $34.4M | $15.1M | +77.70% |
| Q2 2020 | 2020-06-30 | $20.1M | −$5.7M | −22.13% |
| Q1 2020 | 2020-03-31 | $23.9M | −$7.1M | −22.91% |
| Q4 2019 | 2019-12-31 | $14.5M | −$21.7M | −59.99% |
| Q3 2019 | 2019-09-30 | $19.4M | −$18.3M | −48.55% |
| Q2 2019 | 2019-06-30 | $25.8M | −$21.4M | −45.34% |
| Q1 2019 | 2019-03-31 | $31.0M | −$45.6M | −59.48% |
| Q4 2018 | 2018-12-31 | $36.2M | −$56.4M | −60.89% |
| Q3 2018 | 2018-09-30 | $37.7M | −$63.6M | −62.79% |
| Q2 2018 | 2018-06-30 | $47.2M | −$65.8M | −58.21% |
| Q1 2018 | 2018-03-31 | $76.6M | −$23.3M | −23.31% |
| Q4 2017 | 2017-12-31 | $92.6M | −$18.3M | −16.49% |
| Q3 2017 | 2017-09-30 | $101.2M | −$15.3M | −13.16% |
| Q2 2017 | 2017-06-30 | $113.0M | −$2.4M | −2.11% |
| Q1 2017 | 2017-03-31 | $99.9M | −$23.9M | −19.28% |
| Q4 2016 | 2016-12-31 | $110.9M | −$23.2M | −17.29% |
| Q3 2016 | 2016-09-30 | $116.6M | $58.1M | +99.34% |
| Q2 2016 | 2016-06-30 | $115.4M | — | — |
| Q1 2016 | 2016-03-31 | $123.8M | — | — |
| Q4 2015 | 2015-12-31 | $134.1M | $117.2M | +695.97% |
| Q3 2015 | 2015-09-30 | $58.5M | — | — |
| Q4 2014 | 2014-12-31 | $16.8M | — | — |
PDS Biotechnology total assets trends
Over the last five fiscal years, PDS Biotechnology's total assets decreased from $30.9M to $30.5M, a change of −$396,296. The latest reported quarter, Q2 2026, shows $8.8M.
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review PDS Biotechnology source filings ↗